GNH USA

Europe — EMA

Nitisinone Dipharma

GNH USA supplies Nitisinone Dipharma (Nitisinone), a HPPD inhibitor for hereditary tyrosinemia type I. Request a quote for global supply, available worldwide.

Nitisinone

Request sourcing

1
Pack/s

What is Nitisinone?

Nitisinone, the active ingredient in Nitisinone Dipharma, is a 4‑hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor presented as an oral formulation for systemic use. It blocks the formation of toxic metabolites in the tyrosine degradation pathway and is indicated for the treatment of hereditary tyrosinemia type I in affected patients.

GNH USA supplies Nitisinone Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution.

What is Nitisinone used for?

Nitisinone acts on the tyrosine catabolic pathway and is employed in the management of hereditary metabolic disorders.

- Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites, preventing liver and renal complications. - Tyrosinemia type I pre‑transplant preparation: stabilises metabolic status before liver transplantation. - Long‑term metabolic control in tyrosinemia type I: maintains low levels of harmful intermediates to support normal growth and development.

What are the side effects of Nitisinone?

Nitisinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: occasional gastrointestinal upset. - Abdominal pain: intermittent discomfort. - Fatigue: reduced energy levels. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate hepatic stress. - Hypoglycaemia: low blood sugar requiring monitoring. - Peripheral neuropathy: tingling or numbness in extremities. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hematologic abnormalities: including anemia or thrombocytopenia.

What precautions apply to Nitisinone?

Before initiating therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess transaminases regularly. - Blood glucose surveillance: watch for hypoglycaemic episodes. - Renal function assessment: adjust use in severe impairment. - Hypersensitivity caution: discontinue if allergic reactions occur. - Pregnancy and lactation: avoid use as safety data are lacking. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

What does Nitisinone interact with?

Nitisinone can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent HPPD inhibitors: additive toxicity risk. - Strong CYP inducers (e.g., rifampicin): may reduce plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Phenobarbital: possible reduction in nitisinone levels. - Vitamin B6 supplements: may influence tyrosine metabolism. - Sulfonamide antibiotics: could alter gut flora and affect drug handling.

Frequently asked questions

What is Nitisinone Dipharma used for?+
Nitisinone Dipharma contains the HPPD inhibitor nitisinone and is used to treat hereditary tyrosinemia type I, a rare metabolic disorder that causes toxic buildup of tyrosine metabolites. The drug helps prevent liver, kidney and neurological complications associated with the disease.
How does nitisinone work?+
Nitisinone blocks the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. By inhibiting this step, it stops the formation of harmful downstream metabolites such as fumarylacetoacetate and succinylacetone, thereby protecting liver and renal tissue from damage.
What is the usual dose of nitisinone?+
The dose of nitisinone is individualized by the prescribing physician based on the patient’s age, weight, disease severity and laboratory monitoring. Dosage adjustments are made according to therapeutic response and safety parameters, and patients should follow the prescriber’s specific instructions.
Is nitisinone safe in pregnancy or breastfeeding?+
Safety data for nitisinone during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally recommended to avoid use in pregnant or nursing women unless the potential benefit outweighs the possible risk, and this decision should be made by a specialist.
How do I order Nitisinone Dipharma from GNH USA?+
To request Nitisinone Dipharma, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.
How does nitisinone compare with the main alternative drug or class?+
The primary alternative to nitisinone is liver transplantation, which removes the metabolic defect but carries surgical risk. Pharmacologically, nitisinone offers a non‑invasive, disease‑modifying approach by directly inhibiting the toxic pathway, allowing many patients to avoid or postpone transplantation while maintaining metabolic control.
How should Nitisinone Dipharma be stored and handled?+
Store the product at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack or container, protect them from moisture, heat and direct sunlight. Do not refrigerate or freeze the medication, and keep it out of reach of children.
How is Nitisinone Dipharma administered?+
Nitisinone Dipharma is taken orally, usually with a glass of water. The exact timing (e.g., with or without food) and frequency are determined by the prescribing clinician based on individual therapeutic goals and tolerability.
What are the most serious risks to watch for while taking nitisinone?+
Serious risks include elevated liver enzymes indicating hepatic stress, hypoglycaemia that may require glucose monitoring, peripheral neuropathy, severe skin reactions such as Stevens‑Johnson syndrome, and hematologic abnormalities like anemia or low platelet counts. Patients should report any unusual symptoms promptly.
Who should not use Nitisinone Dipharma?+
Nitisinone should be avoided in individuals with known hypersensitivity to the drug or any HPPD inhibitor, in patients with severe hepatic impairment where monitoring is not feasible, and in pregnant or breastfeeding women unless a specialist determines that the benefits outweigh the risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nitisinone
Route
Oral Use
Manufacturer
Dipharma Arzneimittel Gmbh
Origin
EU

Related products

Nitisinone 2 mg/1

Nitisinone 2 mg/1

Nitisinone · 2 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 5 mg/1

Nitisinone 5 mg/1

Nitisinone · 5 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 10 mg/1

Nitisinone 10 mg/1

Nitisinone · 10 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Mdk-Nitisinone 2 mg

Mdk-Nitisinone 2 mg

Nitisinone · 2 MG

Mdk-Nitisinone
CAPSULE
MENDELIKABS INC
CANADA